Welcome to CURA

Let's configure your regulatory intelligence workspace.

Are you an HCP or a manufacturer?

Select your primary role in the healthcare ecosystem.

Autonomous Healthcare Analytics

Intelligence-Driven Healthcare Decisions Start Here

CURA is the trusted Healthcare Data Intelligence platform for pharmaceutical companies, medical device manufacturers, healthcare providers, and life sciences investors β€” delivering precision analytics, regulatory intelligence, and market insight across the full healthcare value chain.

The CURA Difference

The Healthcare Intelligence Platform Built for High-Stakes Decisions

The healthcare and life sciences sector generates more data than any other industry on Earth β€” yet most organizations remain data-rich and insight-poor. Siloed systems, fragmented datasets, and regulatory complexity create a gap between information and decision-making that costs companies time, capital, and competitive advantage.

CURA closes that gap.

We are a specialized Healthcare Business Intelligence provider sitting at the intersection of data science, regulatory expertise, and strategic market research. Our platform curates, validates, and synthesizes healthcare data from thousands of structured and unstructured sources β€” transforming raw signals into actionable intelligence that executives, researchers, and strategists can act on immediately.

Whether you're a pharmaceutical company tracking a competitor's pipeline, a medical device manufacturer navigating FDA premarket pathways, a healthcare investor evaluating a clinical-stage asset, or a consulting firm building a market entry strategy β€” CURA delivers the intelligence layer that powers your next move.

Activity Analytics

35-Day Regulatory Activity Index

Visualize frequency and trend transformations of regulatory updates. Tap the categories below to filter indices in real time.

πŸ“† Live: Last 30 Days Trend
  • AI & Tech
  • Biomedical
  • Finance
Jul 07Jul 09Jul 11Jul 13Jul 15Jul 17Jul 19Jul 21Jul 23Jul 25Jul 27Jul 29Jul 31Aug 02Aug 04Aug 06Aug 08Aug 100255075100
Core Solutions Directory

What We Do: End-to-End Healthcare Data Intelligence

Flagship Product

European Procedure Intel

Pinpoint surgical and diagnostic hotspots across major European markets. Equip your commercial teams with precision facility-level volume data to target the right hospitals.

Market Competitive Intelligence

Automate tracking across millions of public databases, news feeds, and competitor journals. Leverage AI deep deduplication, analyst tagging, regulatory scraping pipelines, and custom alert newsletters.

Hospital Intelligence

Modelled after the gold-standard GHI trackers, analyze cumulative hospital demographics (Facility Demographics), OEM equipment brand market shares (OEM Market Share), surgical volume growth trends (Surgical Volumes), and active upgrade tenders.

Healthcare Data Intelligence

Structured, validated intelligence derived from claims data, EHR analytics, disease burden mapping, treatment pattern analysis, and epidemiological datasets. We translate complex population health signals into clear strategic guidance.

Pharmaceutical Data Intelligence

Track drug pipelines, approval timelines, patent landscapes, pricing dynamics, and competitive drug repositioning across therapeutic areas. Our Drug Intelligence service covers FDA, EMA, PMDA, CDSCO, and 30+ global regulatory bodies.

Biomedical Device Intelligence

Monitor medical device approvals, recalls, adverse event reports, CE Mark certifications, and 510(k)/PMA submission activity. Our Biomedical Device Intelligence service gives manufacturers and investors a comprehensive lens on device market dynamics.

Healthcare Analytics & Reporting

Our Healthcare Analytics engine processes multi-source data into decision-ready dashboards, longitudinal trend reports, cohort analysis, and customized data visualizations β€” built for the tempo of enterprise healthcare decisions.

Regulatory Intelligence

Stay ahead of global regulatory change with real-time monitoring of submission guidelines, approval pathway updates, compliance mandates, and agency guidance documents across 30+ regulatory authorities.

Custom Healthcare Market Research

When standard datasets aren't enough, our bespoke research practice delivers primary research studies, KOL panel analysis, competitive benchmarking, and precision market sizing tailored to your specific strategic questions.

Generative Market Report Studio

Instantly synthesize millions of data points from ClinicalTrials, PubMed, and OpenFDA into executive-ready PDF briefings using the CURA AI Agent.

Patient Journey Analytics (RWE)

Visualize real-world treatment sequencing and longitudinal patient pathways derived from anonymized Electronic Health Records (EHR) and Claims databases.

M&A Target Predictor

Analyze patent cliffs and clinical trial results to calculate AI Synergy Scores, predicting the most likely acquisition targets for big pharma.

KOL Social Graph

Visualize Key Opinion Leaders as an interactive network graph to see who co-authors papers and influences specific therapeutic areas.

Supply Chain Predictor

Predict global drug shortages by correlating FDA 483 warning letters issued to API manufacturers in high-risk regions.

Regulatory Divergence Tracker

Identify global compliance risks when the FDA approves a drug but the EMA rejects it, visualizing divergent regulatory decisions.

Real-Time Healthcare Intelligence

Live FDA, Clinical Trials & Hospital Data

These widgets pull directly from openFDA, ClinicalTrials.gov, and modeled global hospital databases. All data is refreshed in near-real time.

Live Biologics & Biosimilar Intelligence

Live openFDA Data β€” Searching Biologics License Applications

Pyzchiva

Mfr: Samsung Bioepis Co Ltd

BLA761373

Route of Admin

Injection

Active Ingredient

Ustekinumab-Ttwe

Submission Status: AP (20240628)

Follistim Aq

Mfr: Organon Usa Llc

BLA021211

Route of Admin

Subcutaneous

Active Ingredient

Follitropin Alfa/Beta

Submission Status: AP (20151109)

Leqembi Iqlik

Mfr: Eisai Inc

BLA761375

Route of Admin

Subcutaneous

Active Ingredient

Lecanemab-Irmb

Submission Status: AP (20260713)

Unknown Biologic

Mfr: Dr Reddys Labs Sa

BLA761376

Route of Admin

Unknown Route

Active Ingredient

Unknown Ingredient

Submission Status: AP (20260731)

Levemir Flextouch

Mfr: Novo Nordisk Inc

BLA021536

Route of Admin

Subcutaneous

Active Ingredient

Insulin Detemir Recombinant

Submission Status: AP (20140225)

Eydenzelt

Mfr: Celltrion Inc

BLA761377

Route of Admin

Injection

Active Ingredient

Aflibercept-Boav

Submission Status: AP (20251002)

Myalept

Mfr: Chiesi Farmaceutici Spa

BLA125390

Route of Admin

Injection

Active Ingredient

Metreleptin

Submission Status: AP (20140224)

Unknown Biologic

Mfr: Halozyme Therap

BLA761313

Route of Admin

Unknown Route

Active Ingredient

Unknown Ingredient

Submission Status: AP (20230620)

Adcetris

Mfr: Seattle Genetics

BLA125399

Route of Admin

Injection

Active Ingredient

Brentuximab Vedotin

Submission Status: AP (20110819)

Alhemo

Mfr: Novo Nordisk Inc

BLA761315

Route of Admin

Subcutaneous

Active Ingredient

Concizumab-Mtci

Submission Status: AP (20241220)

Perjeta

Mfr: Genentech

BLA125409

Route of Admin

Single-Use

Active Ingredient

Pertuzumab

Submission Status: AP (20160322)

Lytenava

Mfr: Outlook Therapeutics, Inc.

BLA761320

Route of Admin

Single-Dose

Active Ingredient

Bevacizumab-Vikg

Submission Status: AP (20260724)

Hylenex Recombinant

Mfr: Halozyme Therap

BLA021859

Route of Admin

Injection

Active Ingredient

Hyaluronidase Recombinant Human

Submission Status: AP (20120301)

Zaltrap

Mfr: Sanofi Aventis Us

BLA125418

Route of Admin

Injection

Active Ingredient

Ziv-Aflibercept

Submission Status: AP (20131025)

Tyruko

Mfr: Sandoz Inc

BLA761322

Route of Admin

Injection

Active Ingredient

Natalizumab-Sztn

Submission Status: AP (20260723)

Jetrea

Mfr: Thrombogenics, Inc

BLA125422

Route of Admin

Intravitreal

Active Ingredient

Ocriplasmin

Submission Status: AP (20160327)

Epkinly

Mfr: Genmab Us, Inc.

BLA761324

Route of Admin

Subcutaneous

Active Ingredient

Epcoritamab-Bysp

Submission Status: AP (20240626)

Pregnyl

Mfr: Organon Usa Llc

BLA017692

Route of Admin

Injection

Active Ingredient

Gonadotropin, Chorionic

Submission Status: AP (19940218)

Kadcyla

Mfr: Genentech

BLA125427

Route of Admin

Single-Use

Active Ingredient

Ado-Trastuzumab Emtansine

Submission Status: AP (20250514)

Merilog

Mfr: Sanofi-Aventis U.S. Llc

BLA761325

Route of Admin

Solution

Active Ingredient

Insulin Aspart-Szjj

Submission Status: AP (20250214)

Tanzeum

Mfr: Glaxosmithkline Llc

BLA125431

Route of Admin

Injection

Active Ingredient

Albiglutide

Submission Status: AP (20171212)

Awiqli Flextouch

Mfr: Novo Nordisk Inc

BLA761326

Route of Admin

Solution

Active Ingredient

Insulin Icodec

Submission Status: AP (20260326)

Simponi Aria

Mfr: Janssen Biotech

BLA125433

Route of Admin

Injection

Active Ingredient

Golimumab

Submission Status: AP (20171020)

Beyfortus

Mfr: Astrazeneca Ab

BLA761328

Route of Admin

Injection

Active Ingredient

Nirsevimab-Alip

Submission Status: AP (20240223)

Vimizim

Mfr: Biomarin Pharm

BLA125460

Route of Admin

Injection

Active Ingredient

Elosulfase Alfa

Submission Status: AP (20251030)

Orphan Drug & Rare Disease Intelligence

Orphan designation Β· Exclusivity tracking Β· Global approvals

Watson Labs Inc β€” Topical

Approved7yr exclusivity
Prevalence: <200,000 (US)Population: Rare DiseaseDesignated: Feb 7, 2006
US FDA βœ“EMA EU PendingPMDA JP Pending

Pharmobedient β€” Oral

Approved7yr exclusivity
Prevalence: <200,000 (US)Population: Rare DiseaseDesignated: Jul 29, 2005
US FDA βœ“EMA EU PendingPMDA JP Pending

Poythress β€” Topical

Approved7yr exclusivity
Prevalence: <200,000 (US)Population: Rare DiseaseDesignated: Sep 17, 1940
US FDA βœ“EMA EU PendingPMDA JP Pending

Natco Pharma β€” Oral

Approved7yr exclusivity
Prevalence: <200,000 (US)Population: Rare DiseaseDesignated: Apr 26, 2019
US FDA βœ“EMA EU PendingPMDA JP Pending

Able β€” Oral

Approved7yr exclusivity
Prevalence: <200,000 (US)Population: Rare DiseaseDesignated: Aug 22, 2003
US FDA βœ“EMA EU PendingPMDA JP Pending

Roxane β€” Oral

Approved7yr exclusivity
Prevalence: <200,000 (US)Population: Rare DiseaseDesignated: May 10, 1976
US FDA βœ“EMA EU PendingPMDA JP Pending

Watson Labs β€” Oral

Approved7yr exclusivity
Prevalence: <200,000 (US)Population: Rare DiseaseDesignated: Jul 8, 1987
US FDA βœ“EMA EU PendingPMDA JP Pending

Ivax Pharms β€” Oral

Approved7yr exclusivity
Prevalence: <200,000 (US)Population: Rare DiseaseDesignated: May 11, 1977
US FDA βœ“EMA EU PendingPMDA JP Pending

Watson Labs β€” Oral

Approved7yr exclusivity
Prevalence: <200,000 (US)Population: Rare DiseaseDesignated: Unknown Date
US FDA βœ“EMA EU PendingPMDA JP Pending

Sanofi Aventis Us β€” Oral, Rectal

Approved7yr exclusivity
Prevalence: <200,000 (US)Population: Rare DiseaseDesignated: Sep 18, 1987
US FDA βœ“EMA EU PendingPMDA JP Pending

Teva Parenteral β€” Subcutaneous

Approved7yr exclusivity
Prevalence: <200,000 (US)Population: Rare DiseaseDesignated: Jul 29, 2008
US FDA βœ“EMA EU PendingPMDA JP Pending

Chartwell Rx β€” Oral

Approved7yr exclusivity
Prevalence: <200,000 (US)Population: Rare DiseaseDesignated: Sep 24, 2012
US FDA βœ“EMA EU PendingPMDA JP Pending

Barr Labs Inc β€” Oral

Approved7yr exclusivity
Prevalence: <200,000 (US)Population: Rare DiseaseDesignated: Nov 29, 2012
US FDA βœ“EMA EU PendingPMDA JP Pending

Alembic Pharms Ltd β€” Oral

Approved7yr exclusivity
Prevalence: <200,000 (US)Population: Rare DiseaseDesignated: May 11, 2020
US FDA βœ“EMA EU PendingPMDA JP Pending

Septodont Inc β€” Injection

Approved7yr exclusivity
Prevalence: <200,000 (US)Population: Rare DiseaseDesignated: Nov 2, 2018
US FDA βœ“EMA EU PendingPMDA JP Pending

Dr Reddys β€” Injection

Approved7yr exclusivity
Prevalence: <200,000 (US)Population: Rare DiseaseDesignated: Aug 6, 1986
US FDA βœ“EMA EU PendingPMDA JP Pending

Esi β€” Oral

Approved7yr exclusivity
Prevalence: <200,000 (US)Population: Rare DiseaseDesignated: Nov 28, 1997
US FDA βœ“EMA EU PendingPMDA JP Pending

Alra β€” Oral

Approved7yr exclusivity
Prevalence: <200,000 (US)Population: Rare DiseaseDesignated: Jul 21, 1982
US FDA βœ“EMA EU PendingPMDA JP Pending

Pharmeral β€” Oral

Approved7yr exclusivity
Prevalence: <200,000 (US)Population: Rare DiseaseDesignated: May 8, 1974
US FDA βœ“EMA EU PendingPMDA JP Pending

Torrent Pharms β€” Oral

Approved7yr exclusivity
Prevalence: <200,000 (US)Population: Rare DiseaseDesignated: Oct 13, 2016
US FDA βœ“EMA EU PendingPMDA JP Pending

Pfizer β€” Oral

Approved7yr exclusivity
Prevalence: <200,000 (US)Population: Rare DiseaseDesignated: Jan 6, 1998
US FDA βœ“EMA EU PendingPMDA JP Pending

Rising β€” Injection

Approved7yr exclusivity
Prevalence: <200,000 (US)Population: Rare DiseaseDesignated: Aug 28, 2012
US FDA βœ“EMA EU PendingPMDA JP Pending

Udl β€” Oral

Approved7yr exclusivity
Prevalence: <200,000 (US)Population: Rare DiseaseDesignated: Unknown Date
US FDA βœ“EMA EU PendingPMDA JP Pending

Actavis Mid Atlantic β€” Oral

Approved7yr exclusivity
Prevalence: <200,000 (US)Population: Rare DiseaseDesignated: Jun 3, 1991
US FDA βœ“EMA EU PendingPMDA JP Pending

Abraxis Pharm β€” Injection

Approved7yr exclusivity
Prevalence: <200,000 (US)Population: Rare DiseaseDesignated: Unknown Date
US FDA βœ“EMA EU PendingPMDA JP Pending
Empirical Validation

Why Global Healthcare Organizations Trust CURA

500+

Healthcare Datasets Monitored

50+

Global Regulatory Agencies Covered

10M+

Data Points Processed Monthly

150+

Enterprise Clients Served

75+

Countries with Data Coverage

95%

Client Retention Rate

TRUSTED PARTNERS ACROSS LIFE SCIENCES

Top-10 Pharmaceutical CompaniesGlobal Medtech OEMsLeading US Hospital SystemsLife Sciences PE / VC Firms
Market Scope

Industries We Power With Healthcare Intelligence

CURA serves the full spectrum of life sciences and healthcare:

Pharmaceutical & Biotech Companies

Pipeline intelligence, competitive benchmarking, market access analytics

Medical Device & Diagnostics Manufacturers

Approval tracking, recall monitoring, market sizing

Healthcare Providers & Hospital Systems

Operational benchmarks, utilization analytics, payer intelligence

Life Sciences Investors & Private Equity

Due diligence data, clinical asset scoring, market opportunity mapping

Healthcare Consulting Firms

White-label intelligence, rapid-turnaround datasets, sector deep dives

Academic & Clinical Research Organizations

Epidemiological data, trial landscape analysis, publication intelligence

Case Study Portfolio

How a Global Pharma Leader Cut Market Entry Time by 40%

Challenge:

A top-20 global pharmaceutical company needed competitive landscape intelligence for a new oncology asset ahead of a European launch.

Solution:

CURA deployed its Pharmaceutical Data Intelligence platform to map competitor positioning, regulatory approval timelines, and prescriber behavior in six target markets.

Result:

The client reduced strategic planning time by 40%, identified two unserved patient segments, and achieved first-quarter sales exceeding internal projections by 28%.

"CURA gave us the intelligence clarity we needed to go to market with precision, not guesswork."

β€” Chief Strategy Officer, Global Pharmaceutical Company (Anonymized)

Interactive Platform Demo Mode

Live Platform Telemetry: Real-Time Intelligence Stream

Explore active drug approvals, medical news monitoring, and earnings transcript summaries generated by CURA's backend models:

Transcript Intelligence

Abbott Laboratories - Q2 2026

2026-07-20

Medical Devices sales grew 14%, fueled by FreeStyle Libre and electrophysiology.

Source: Yahoo Finance

Medtronic - Q4 2026

2026-06-03

Strong Q4 performance, reporting $9.8B in revenue driven by Cardiac Ablation Solutions.

Source: Seeking Alpha

Stryker - Q1 2026

2026-04-30

Organic sales growth of 11.8% led by MedSurg and Neurotechnology segments.

Source: Perplexity Finance

Boston Scientific - Q1 2026

2026-04-24

Operational revenue growth of 13.1% driven by cardiovascular portfolio.

Source: Seeking Alpha

Intuitive Surgical - Q1 2026

2026-04-18

Continued adoption of da Vinci systems and strong procedural growth worldwide.

Source: Manufacturer Website

PMDA Approval Updates (Monthly)

Biologic Asset

Drug

2026-07-31

LEQEMBI IQLIK

Drug

2026-07-13

PYZCHIVA

Drug

2024-06-28

FOLLISTIM AQ

Drug

2015-11-09

LEVEMIR FLEXTOUCH

Drug

2014-02-25

*Data processed from PMDA official PDF publications. Next update scheduled in 1 month.

Live Feed Curation & Tagging Engine

CURA Intelligence Tracker

Continuous cross-border crawling across FDA, EMA, clinical registries, and patent archives. Tagged automatically by Event Bucket, Region, Impact Level, & Therapeutic Class.

Monitored10 Feeds
High Risk1 Warnings
Showing 10 of 10 parsed intelligence assets
Article cover
High Impact

EMA issues urgent safety advisory for cardio implant components

The European Medicines Agency has identified a potential safety issue regarding certain batches of cardiovascular stents.

European UnionCardiologyRecalls
CURA Intelβ€’2 min read
View Analysis
Article cover
Low Impact

MHRA issues new guidance on AI as a Medical Device

The UK Medicines and Healthcare products Regulatory Agency has updated its regulatory roadmap for software and AI.

United KingdomDigital Health/SaMDGeneral News
CURA Intelβ€’1 min read
View Analysis
Article cover
Medium Impact

TGA clears new AI software as a medical device for oncology

Australia's TGA has granted clearance for an AI-based diagnostic tool intended to assist in melanoma detection.

APAC/AmericasOncologyApproval
CURA Intelβ€’2 min read
View Analysis
Article cover
Low Impact

FARADRIVE STEERABLE SHEATH CLEAR, used to facilitate access to the vasculature a...

Boston Scientific's complaint investigations have identified that a subset of air ingress complaints are associated with hemostatic valve damage related to dilator insertion orientation during device preparation. Valve damage may result in air ingress, potential air embolism, and associated patient harm. This risk can be mitigated by inserting the dilator straight through the center of the valve and fully advancing it into the sheath body.

USAGeneral MedicineGeneral News
CURA Intelβ€’2 min read
View Analysis
Article cover
Low Impact

FARASTAR Ablation Generator EU, Pulsed Field Ablation Generator, Product ID 61M4...

Boston Scientific is replacing specific FARASTAR PFA generators which have a configuration that is not compatible for use with the FARAPOINT PFA catheter.

USAGeneral MedicineGeneral News
CURA Intelβ€’2 min read
View Analysis
Article cover
Low Impact

Halyard STANDARD LINE INSERTION PACK. Model/Catalog Number: PVHM234-01. Conv...

Defects in the silicone seal, which may result in "doming" of the silicone seal due to improper sealing, potentially leading to fluid occlusion or leakage.

USAGeneral MedicineGeneral News
CURA Intelβ€’2 min read
View Analysis
Article cover
Low Impact

Penumbra System RED 68 Reperfusion Catheter REF: RED68KIT...

Due to manufacturing issues, reperfusion catheters may fractures

USAOrthopedicsGeneral News
CURA Intelβ€’2 min read
View Analysis
Article cover
Low Impact

SafeOp Patient Interface, REF: AIX11240, part of SafeOp 3: Neural Informatix Sys...

Intraoperative neuromonitoring device, due to a software issue, may experience loss or interruption of triggered electromyography (tEMG) functionality during use, displaying as system faults, loss of communication between the Patient Interface and Tablet, and prompts requiring system reboot; may result in increased operative time and surgical plan change.

USANeurologyGeneral News
CURA Intelβ€’2 min read
View Analysis
Article cover
Low Impact

MiniMed Go App, Model: MMT-8600 (iOS), MMT-8601 (Android)...

For MiniMed Go app version 1.0.0 and 1.1.0, when the Set day and night is turned OFF and missed dose or Correct high glucose alerts are enabled, the associated alerts will not be triggered during the nighttime. This could result in missed rapid-acting insulin doses without the user s knowledge, and may lead to delayed therapy and an increased risk of hyperglycemia.

USADigital Health/SaMDGeneral News
CURA Intelβ€’2 min read
View Analysis
Article cover
Low Impact

FARASTAR Ablation Generator EU, Pulsed Field Ablation Generator, Product ID 61M4...

Labeling discrepancy: Devices distributed with Instructions For Use (IFU) did not include FARAPOINT PFA catheter information.

USAGeneral MedicineGeneral News
CURA Intelβ€’2 min read
View Analysis

Start With Intelligence. Lead With Confidence.

Healthcare is too complex, too regulated, and too competitive to navigate on incomplete information. CURA gives you the data infrastructure, analytical depth, and domain expertise to make decisions that matter β€” faster than your competition.